Learn More
PURPOSE To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line treatment of advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS This multicenter, open-label,(More)
PURPOSE This study assessed the efficacy of the combination of standard taxane plus platinum chemotherapy with the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in(More)
8021 Background: This phase III study investigated cetuximab (C) plus taxane/carboplatin (TC) in 1st-line advanced NSCLC. Progression-free survival (PFS) was not significantly different with the(More)
7085 Background: Targeting VEGF has proven to be an effective tx strategy in many solid tumors including non-small cell lung cancer. VEGF expression in SCLC provides rationale for studying B in(More)
  • 1